Using this 5–cell type model, we found that KRAS mutations and the secretion rate of EGF from cancer cells were associated with Bailey subtypes while TP53 mutations and EGF secretion rate were associated with the Moffitt subtypes, indicating their potential clinical significance. This evidence concerns the gene KRAS and cancer.